Blood glucose monitoring systems (BGMS) are often used by diabetes patients on an insulin regimen as basis for their therapeutic decisions, like administration of insulin or rescue carbohydrates. Accuracy of the results displayed by BGMS is therefore an important issue in the use of BGMS, because only sufficiently high accuracy allows diabetes patients ade quate diabetes control.
other hand is inversely related to random measurement errors that lead to differences within replicate measurement results. Both of these concepts play a role in assessing the reliability of measurement results from a BGMS, because a high level of accuracy can only be achieved if the measurement results are sufficiently true and precise.
ISO 15197:2013 requirements regarding analytical perfor mance of BGMS include assessment of system accuracy in the hands of trained professionals, whose results can also be used for bias estimation, and assessment of precision under varying measurement conditions over an extended period of time (intermediate measurement precision) and under similar measurement conditions over a short period of time (mea surement repeatability). ISO 15197:2013 was harmonized as EN ISO 15197:2015 with regulations of the European Union, without changes to the requirements and procedures.
This study focused on assessments of system accuracy, intermediate measurement precision, and measurement repeatability of the blood glucose monitoring functionality of a multifunctional monitoring system.
Methods
This study was performed at the Institut für Diabetes Technologie, Forschungs und Entwicklungsgesellschaft mbH an der Universität Ulm (IDT) in Germany between November 2017 and January 2018. Prior to subject recruit ment, the study was approved by the responsible ethics com mittee, and exempted from approval by the competent authority. All local regulations and requirements of Good Clinical Practice (DIN EN ISO 14155:2012) were followed.
IDT is a testing laboratory accredited according to DIN 
Blood Glucose Monitoring System
The BGMS used in this study was the BG monitoring func tionality of the FORA® 6 Connect (GD82) Multifunctional Monitoring System (ForaCare Suisse AG, St. Gallen, Switzerland). System characteristics are shown in Table 1 .
This multifunctional system can be used with different types of test strips that allow for measurement of BG, hema tocrit, hemoglobin, βketone, total cholesterol, and uric acid concentrations. In this study, the system was used with BG test strips.
Study Procedures
System accuracy. System accuracy testing was performed based on requirements of ISO 15197:2013. To obtain the required number of 100 evaluable data sets, 113 subjects were enrolled. Before BGMS measurements with each of 3 reagent system lots were conducted, subjects were asked to wash and dry their hands. Study personnel subsequently collected a capillary blood sample from the subject's fin gertip by skin puncture and measured the sample's glucose concentration in duplicate with 2 test meters using test strips from the same vial. This step was repeated for all three reagent system lots with, in total, 6 meters. Room temperature was checked to be within 23°C ± 5°C and humidity was checked to be within the range indicated in the manufacturer's labelling during each measurement. The hematocrit value was checked to be within the range of 0% and 70% based on the manufacturer's measurement specifi cations on an additional sample. Hematocrit values were determined with an alignment chart after sample centrifu gation in heparinized capillaries.
Comparison values were obtained using a hexokinase based method (Cobas Integra® 400 plus; Roche Instrument Center, Rotkreuz, Switzerland), because the manufacturer's reference method is also hexokinasebased. Based on daily measurements with standard reference material 965b of the National Institute of Standards and Technology (Gaithersburg, MD) with four target concentrations, bias ranged from 0.1% to 1.7%, and CV was ≤2.4%.
Aliquots for comparison measurements were collected before and after a sample's glucose concentration was mea sured with all 3 of the test strip lots. After centrifugation of the respective blood samples, measurements were performed in duplicate in capillary plasma.
The stability of the samples' glucose concentrations was verified by calculating the difference in glucose concentrations between the two consecutively drawn aliquots. Results were checked to be ≤4 mg/dl at glucose concentrations ≤100 mg/dl and ≤4% at glucose concentrations >100 mg/dl, otherwise data were excluded. BG concentrations of samples were distributed according to ISO 15197:2013 over the clinically relevant concentration range (5% ≤50 mg/dl, 15% >50 to 80 mg/dl, 20% >80 to 120 mg/dl, 30% >120 to 200 mg/dl, 15% >200 to 300 mg/ dl, 10% >300 to 400 mg/dl, and 5% >400 mg/dl). The assignment of samples to the applicable concentration range was based on the average of the comparison method mea surement results.
Adjustment of glucose concentrations by glycolysis or glucose supplementation was allowed to obtain samples with glucose concentrations <50 and >400 mg/dl, however, unaltered samples were preferred over altered samples for data evaluation. Oxygen partial pressure of altered samples was checked to be within the range of 55 to 100 mmHg by using a blood gas analyzer (OPTI™ CCATS, OPTI Medical Systems Inc, Roswell, GA, USA). 2 Altered samples were applied to the test strip from a syringe; unaltered samples were applied directly from the fingertip.
Blood samples for adjustment of glucose concentrations measured with the BGMS and the comparison method, as well as all samples for comparison measurements were col lected in lithiumheparin tubes. Unadjusted glucose samples for BGMS measurement were measured directly from the fingertip.
Intermediate measurement precision. Intermediate measure ment precision was evaluated based on ISO 15197:2013. Three control solution samples representing glucose concen trations from 30 to 50 mg/dl, 96 to 144 mg/dl and 280 to 420 mg/dl were measured once with each of 10 test meters per test strip lot and day. Measurements were performed by 2 users (each user performed 5 measurements per control solu tion interval, test strip lot and day) on 10 subsequent days with 3 test strip lots resulting in a total of 900 separate BGMS measurements which were performed under environmental conditions as specified by the manufacturer.
Additional measurements were performed in duplicate with a YSI 2300 STAT Plus (YSI Inc, Yellow Springs, OH) glucose analyzer in aliquots of the same control solution samples to assess sample stability on each day and over the course of all 10 days using the stability criteria mentioned above. YSI 2300 STAT Plus was used, because Cobas Integra 400 plus was not intended to be used with aqueous samples according to the manufacturer's labeling.
Measurement repeatability. Based on requirements of ISO 15197:2013, the repeatability test was performed with 10 test meters and 3 reagent system lots on 5 venous blood samples collected in lithiumheparin tubes. Samples from 5 different subjects and with the following glucose concentration ranges stipulated by ISO 15197:2013 were collected: (1) 30 to 50 mg/ dl, (2) 51 to 110 mg/dl, (3) 111 to 150 mg/dl, (4) 151 to 250 mg/ dl, (5) 251 to 400 mg/dl. Glucose concentrations of the samples were measured 10 times with each of the 10 test meters by a single user on 5 consecutive days. With a specific sample, all measurements with the 3 different test strip lots were performed on the same day. BGMS measurements were performed under environmental conditions as specified by the manufacturer. Sample temperature was checked to be within 23°C ± 5°C before starting the first measurement for a specific sample and it was not allowed to differ more than ±2°C from that value until the last measurement for the same sample.
Additional measurements were performed in duplicate with a Cobas Integra 400 plus glucose analyzer in aliquots of the same samples to assess sample stability over the course of measurements. Stability criteria were the same as for sys tem accuracy evaluation.
Data Analysis
Data management and evaluation was performed based on requirements of ISO 15197:2013 at the study site.
System accuracy. As first criterion, ISO 15197:2013 requires ≥95% of measurement values per reagent system lot either falling within ±15 mg/dl at glucose concentra tions <100 mg/dl or within ±15% at glucose concentra tions ≥100 mg/dl. For data analysis, the difference between each of the 200 BGMS measurements per test strip lot and the corresponding mean comparison method result was calculated. Accuracy results were visualized in a differ ence plot (Figure 1) . Second, the relative number of data points falling within the clinically acceptable zones A and B of the consensus error grid 3 (CEG) was calculated for all of the 3 reagent system lots taken together.
The relative bias of the measurement results was deter mined according to Bland and Altman 4 for each reagent sys tem lot and the percentage distribution of all data points into the 8 different zones of the surveillance error grid (SEG) was calculated using the SEG software. 5, 6 Data were excluded from evaluation if the change between first and second comparison duplicate measurement indi cated unstable glucose concentrations, if the CV within a comparison duplicate measurement was >5%, if the study personnel documented a procedurerelated error, in case of hemolytic sample, or if a sufficient number of samples within a glucose concentration category was already reached.
Intermediate measurement precision. For data evaluation, mean value, standard deviation (for BGMS results <100 mg/dl) and coefficient of variation (CV) (for BGMS results >100 mg/dl) were calculated for each test strip lot and analysis of variance components was performed for the following factors: meter, reagent system lot, reagent system vial, user, and measure ment day.
On the eighth day, one BG meter had to be replaced because of a device deficiency. Data that were obtained with the deficient meter on the day of replacement were excluded from analysis. Using the replacement meter, all scheduled measurements were repeated.
Measurement repeatability.
For each glucose concentration (ie, sample), the mean BGMS result and the standard devia tion (SD) or the coefficient of variation (CV) (for samples with mean BGMS result <100 mg/dl or ≥100 mg/dl, respec tively) were calculated for each test strip lot separately.
No data were excluded. Measurements were repeated in case of the BGMS showing an error message.
Results

System Accuracy
Glucose concentrations ranged from 40 mg/dl to 456 mg/dl, and samples were distributed by glucose concentration accord ing to requirements of ISO 15197:2013.
Between 99.0% and 99.5% of BGMS results were found within ±15 mg/dl or ±15% of comparison method results, which is consistent with ISO criteria (Table 2) . Applying more stringent criteria described in ISO 15197:2013, 86.0% to 90.0% were found within ±10 mg/dl or ±10%, and 57.5% to 61.5% were found within ±5 mg/dl or ±5%.
Difference plots for the three test strip lots are shown in Figure 1 .
CEG analysis showed that all measurement results fell within the clinically acceptable zones A and B which is con sistent with ISO criteria (Table 2) .
In SEG analysis, 2.50% of data pairs were found in the zone associated with slight risk of either a hypoglycemic or a hyperglycemic event. All other results were associated with no risk (risk score ≤0.5) ( Table 2 ).
The comparison of BGMS results and the hexokinase based method's results revealed negative biases for all test strip lots ranging from 2.3% to 3.9% (Table 2 ). For com parison method results of <75 mg/dl, BGMS results were predominantly found to be lower than comparison method results (ie, negatively biased). Bias, ie, the systematic measurement difference between the blood glucose monitoring system and the reference method, was calculated according to Bland and Altman. 
Intermediate Measurement Precision
Intermediate measurement precision yielded an SD of ≤2.2 mg/dl for samples with glucose concentrations of <100 mg/dl and a CV of ≤2.3% for samples with glucose concentrations ≥100 mg/dl (Table 3) . Analysis of variance was performed for the following components: BGMS meter, test strip vial (dependent from the meter), test strip lot, user, and measurement day.
Considering the low SD and CV found in this study, none of the evaluated components had a systematic, relevant effect on the intermediate measurement precision's outcome com pared to residual effects which were defined as part of the total variance which cannot be explained with the stated vari ance components.
Measurement Repeatability
The repeatability testing resulted in an SD of ≤2.1 mg/dl for samples with blood glucose concentrations <100 mg/dl and in a CV of ≤2.4% at glucose concentrations ≥100 mg/dl (Table 4) .
Discussion
System accuracy and measurement precision (intermediate measurement precision and measurement repeatability) of a BGMS were assessed in this study based on ISO 15197:2013 requirements. Both aspects indicate how reliable measure ment results from the investigated BGMS are. System accu racy shows how well individual results match the "true" glucose concentration (estimated by the corresponding com parison results). Depending on the magnitude, differences can affect therapeutic decisions to a relevant degree. These results are supplemented by precision analysis, because the level of variability between results from replicate measure ments in the same sample becomes apparent.
ISO 15197:2013 requirements regarding system accuracy were fulfilled by the investigated system with at least 99% of results within the specified differences of ±15 mg/dl or ±15% and 100% of results in the clinically acceptable CEG zones A and B. In SEG analysis, almost all results were found in the "no risk" zone, the remaining results were associated with a slight risk of hypo or hyperglycemia. Both types of error grid analysis are intended to assess the clinical risk asso ciated with BGMS results, and both types of analysis are based on survey results. Whereas the CEG analysis distrib utes pairs of BGMS and comparison results into five different risk zones, 3 SEG analysis provides more detail by associating these pairs to risk scores on a nearcontinuous scale. 5 Diabetes patients may not be aware of test strip lottolot differences in bias, thus expecting no systematic differences between their measurement results, so that varying bias may lead to reduced quality of diabetes therapy. Substantial lotto lot variability regarding bias was reported in some studies. 79 However, bias analysis in this study showed only small differ ences between the three test strip lots.
Put into context of reports for other BGMS in the litera ture, 1013 the investigated BGMS showed similar results in the precision analysis (SD ≤2.2 mg/dl and CV ≤2.3% for intermediate precision analysis with control solution sam ples, and SD ≤2.1 mg/dl and CV ≤2.4% for measurement repeatability with blood samples). However, verification of compliance with established guidelines was not possible, because neither ISO 15197:2013 nor FDA requirements for overthecounter BGMS stipulate minimum requirements for 15 although a different methodological approach is used, so that results may not be directly comparable.
As required by ISO 15197:2013, glucose measurements were performed in a controlled environment by trained per sonnel, so that results may not be completely representative of the accuracy as perceived by diabetes patients. BGMS often show more accurate results in the hands of trained pro fessionals than in the hands of layusers, 1622 and ambient conditions like temperature are also known to possibly affect the measurement results. 23, 24 In addition, transport and stor age conditions might differ from those experienced by users, because meters, test strips, and control solution were pro vided by the manufacturer, and thus procured through differ ent channels than those available to users.
In the past, measurement performance of some BGMS was found to be inadequate, 2528 so that the assumption that BGMS available on the market perform sufficiently well may be unfounded. To provide patients with the necessary tools for adequate diabetes therapy, BGMS performance should be assessed independently both before and after mar ket introduction of BGMS.
Conclusion
In this study, the investigated BGMS fulfilled system accu racy requirements of ISO 15197:2013, and precision analysis showed results similar to what is reported for other BGMS in the literature.
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